Abstract: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.
Type:
Grant
Filed:
March 11, 2010
Date of Patent:
May 15, 2012
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Robert Dicosimo, John Edward Gavagan, Mark Scott Payne, Frederick B. Cooling, III
Abstract: The invention features compositions and methods for characterizing the methylation status of the Vitamin D Receptor (VDR) in neoplasia (e.g., breast carcinoma), selecting an appropriate therapy, and treating the neoplasia (e.g., breast carcinoma).
Type:
Application
Filed:
March 10, 2010
Publication date:
May 10, 2012
Applicant:
The John Hopkins University
Inventors:
Radharani Marik, Christopher B. Umbricht, Martha A. Zeiger
Abstract: A dermatologic peel comprising alpha hydroxyl acid and metal hydroxide nanocomplexes as neutralizing agents to continually reduce the activity of the system when the acid and neutralizer components are mixed. For example, a 30% glycolic acid gel mixed with a fluidized magaldrate neutralizer can be applied to the skin and will self-neutralize to a skin-compatible pH within a few minutes, effectively exfoliating the skin without a separate neutralization step. The peel is advantageously applied from a two-component system that mixes the components.
Type:
Application
Filed:
January 19, 2012
Publication date:
May 10, 2012
Inventors:
R. MacDonald Smith, Otto William Wendel, Archie McBride
Abstract: A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathways are blocked by an antibody targeted therapy agent, antibody fragment, targeted small-molecule chemical compound, low-molecular-weight tyrosine kinase inhibitor, peptide mimetic, anti-sense oligonucleotide (DNA and/or RNA), or ribozyme.
Abstract: A method for improving the sensory properties and resistance of food and drink products, especially uncured meat products, to various kinds of micro-organisms and in particular food spoilage and food poisoning bacteria includes contacting the food or drink product with a composition comprising alkali metal salts having as anions propionate and a co-anion selected from lactate, acetate, and combinations thereof, and as cations potassium and hydrogen, wherein the weight-based ratio of lactate/propionate is in the range of 0 to 20 and the weight-based ratio of acetate/propionate is in the range of 0.05 to 3.5.
Abstract: A cardiac myocyte protective agent, comprising a compound represented by the formula (Ia) below, a pharmaceutically acceptable salt thereof, or a solvate thereof:
Abstract: The method is for monitoring a childbirth process of a pregnant woman. A plurality of cervix dilatation data and fetal positioning data are obtained and fed to a device. A plurality of lactate concentrations is measured at time intervals. The measured lactate concentrations are shown on a display of the device at the time intervals to show a trend of the lactate concentrations. The cervix dilation data and the fetal positioning data are also shown on the display. The lactate concentrations are evaluated to determine whether the lactate concentrations are rising to indicate that an individual lactate threshold value of the pregnant woman has been exceeded. The medical practitioner may also evaluate the cervix dilation data and the fetal positioning data.
Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
Type:
Grant
Filed:
May 5, 2010
Date of Patent:
May 8, 2012
Assignee:
Omeros Corporation
Inventors:
Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.
Type:
Application
Filed:
November 14, 2009
Publication date:
May 3, 2012
Inventors:
Thomas Lisowsky, Sven Eggerstedt, Richard Bloss, Christiane Ostermeyer, Karlheinz Esser, Frank Bürger, Barbara Krug, Yvonne Feil, Kai-Martin Mueller, Delphine Haase
Abstract: The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.
Type:
Application
Filed:
March 26, 2010
Publication date:
May 3, 2012
Applicant:
Pulmatrix, Inc.
Inventors:
Michael M. Lipp, Robert W. Clarke, David L. Hava, Richard Batycky, John Hanrahan
Abstract: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.
Abstract: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.
Type:
Grant
Filed:
March 11, 2010
Date of Patent:
May 1, 2012
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Robert Dicosimo, John Edward Gavagan, Mark Scott Payne, Frederick B. Cooling, III
Abstract: Water-soluble or water-swellable polymers are described, containing a) 20.0 to 98.99 mole percent of one or more independently recurring structural units of the formula (1) and b) 1.0 to 79.99 mole percent of one or more independently recurring structural units of the formula (2), and c) 0.01 to 8.0 mole percent of one or more independently recurring cross-linking structural units, which are obtained from one or more monomers having at least two olefinic double bonds. The polymers are suitable, for example, as thickeners or yield point formers, in particular in cosmetic, dermatological or pharmaceutical compositions.
Type:
Application
Filed:
March 20, 2010
Publication date:
April 26, 2012
Applicant:
CLARIANT FINANCE (BVI) LIMITED
Inventors:
Klug Peter, Dirk Fischer, Thomas Lindner, Matthias Kunze, Wiebke Moeller, Carina Mildner, Sebastiano Lo Vasco
Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.
Abstract: A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides substrates. The concentrated peracid solution produced is sufficient for use in a variety of disinfection and/or bleaching applications.
Type:
Grant
Filed:
September 23, 2009
Date of Patent:
April 24, 2012
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Robert DiCosimo, Mark Scott Payne, Eugenia Costa Hann, Vincent Brian Croud, John Edward Gavagan, Lorraine Winona Wagner
Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Type:
Grant
Filed:
July 28, 2009
Date of Patent:
April 24, 2012
Assignee:
Blanchette Rockefeller Neurosciences Institute
Abstract: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
Type:
Application
Filed:
October 19, 2011
Publication date:
April 19, 2012
Applicant:
APOGEE BIOTECHNOLOGY CORPORATION
Inventors:
Charles D. Smith, Kevin J. French, Yan Zhuang
Abstract: Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or prescriptive or non-prescriptive medication indications for use on the skin, hair, scalp, foot, or lips. Also provided is the use of the topical compositions to deliver the acid(s) to the skin, hair, scalp, foot, or lips. Especially preferred is a use to reduce irritation and stinging compared to an equivalent compositions not having lightly- to moderately-crosslinked PVP.
Type:
Application
Filed:
March 11, 2010
Publication date:
April 19, 2012
Applicant:
ISP INVESTMENTS INC.
Inventors:
Hani Fares, Chris Barrett, Tracey Ross, Anthony Luschen
Abstract: Provided are methods for treating MLL-rearranged ALL by administering to a patient an HDAC inhibitor alone or in combination with a DNA demethylating agent. Also provided are methods of treating MLL-rearranged infant ALL. Methods of treating cells by these agents are also provided. Additionally, disclosed is a method for screening for compounds capable to treat MLL-rearranged ALL, in particular, MLL-rearranged infant ALL. In one embodiment, the HDAC inhibitor is romidepsin.
Abstract: A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition to below 4.6. Topical administration of the composition is preferred and is effective in treating lesions associated infections by viruses such as Herpes simplex. Nasal deliverable forms are effective in treating symptoms due to viruses that cause the common cold. Pharmaceutical compositions for use in the present method are provided.
Type:
Application
Filed:
June 15, 2011
Publication date:
April 19, 2012
Applicant:
LIFE FORCE TECHNOLOGIES, LLC
Inventors:
Thomas W. Konowalchuk, Jack Konowalchuk
Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.
Abstract: The invention relates to unsaturated fatty hydroxy acid derivatives of formula (I), wherein Rn is independent from each other H or linear or branched alkyl group which contain from 1 to 6 carbon atoms and which are possibly substituted by a halogen atom, in particular a fluorine atom, RI is H, F, Cl, Br or CF3, R is H or linear or branched alkyl group which contain from 1 to 6 carbon atoms and which are possibly substituted by a halogen atom, in particular a fluorine atom and 3=n=14. Said derivatives is suitable for producing an anti-radical, anti-inflammatory and antipruritic dermocosmetologic composition and/or for treating keratinisation and pigmentation troubles and/or for improving healing.
Type:
Grant
Filed:
October 20, 2006
Date of Patent:
April 17, 2012
Assignee:
Pierre Fabre Dermo-Cosmetique
Inventors:
Marie Charveron, Roger Tarroux, Pascal Bordat
Abstract: The present invention provides a method for curing Parkinson's disease through regulating VDAC1 (voltage-dependent anion channel 1) protein. Specifically, the present invention provides a pharmaceutical composition for curing PD comprising a VDAC1 protein regulator. The VDAC1 protein regulators comprise an inhibitor of VDAC1 mRNA production, an inhibitor of mitochondrial permeability transition pore (mPTP) formation, and a mitochondrial calcium uptake inhibitor. In addition, the present invention provides a method for curing Parkinson's disease comprising administering a VDAC1 protein regulator to a subject with Parkinson's disease. The present invention could provide a method for curing Parkinson's disease through preventing and/or restoring mitochondrial dysfunction.
Abstract: The present disclosure relates to water dispersible granular pesticide compositions, and methods of making and using the compositions. The pesticide compositions include an inner layer including a first pesticide coated on to a substrate, and an outer layer comprising a second pesticide coated on the inner layer. The outer layer increases the water dispersibility of the granular composition, and protects the first pesticide against hydrolysis and photolysis.
Type:
Application
Filed:
October 12, 2011
Publication date:
April 12, 2012
Applicant:
ECOLAB USA INC.
Inventors:
Victor F. Man, Yvonne M. Killeen, Susan M. Viall
Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
Type:
Application
Filed:
October 6, 2011
Publication date:
April 12, 2012
Applicant:
BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
Inventors:
Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
April 10, 2012
Assignee:
Esperion Therapeutics, Inc.
Inventors:
Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
Abstract: The invention describes novel preparations and their use for reducing the acute damaging effect of ammonia in organisms living in the keeping water of aquariums, garden ponds, or aquaculture systems. The preparations consist of adducts of sodium hydrogen sulfite at an aliphatic aldehyde of the general formula X—(CH2)n—CO—H, wherein n means the numbers 0 to 3, and X means an —OH, —COOH, or —CO—H group, wherein X cannot be —OH, if n=0. The preparations are used in the keeping water with a concentration of 10 to 140 mg/l.
Abstract: The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or calcium citrate as an active ingredient.
Type:
Application
Filed:
March 26, 2010
Publication date:
April 5, 2012
Inventors:
Robert W. Clarke, Richard Batycky, David L. Hava, Michal M. Lipp
Abstract: By incorporating certain pharmaceutical and cosmetic preservative agents into nail polish vehicles containing corrosive ingredients, the risk and prevalence of recurrence of verrucae can be substantially reduced.
Abstract: The present disclosure describes novel standardized citrate replacement fluid solutions and a standardized dialysate solution for use with CRRT methods. The standardized citrate replacement fluid solutions and standardized dialysate solutions do not require modification based on the clinical status of the individual patients. The use of the standardized solutions described herein offers significant advantages over the prior art solutions used in CRRT. The present disclosure describes superior metabolic and electrolyte control and significantly increased dialyzer patency in: (a) 24 intensive care unit (ICU) patients with ARF using a 0.67% trisodium citrate replacement fluid solution, and (b) 32 ICU patients with ARF using a 0.5% trisodium citrate replacement fluid solution. Both groups were treated with Bicarbonate-25 dialysate and achieved effluent rates of 35 mL/kg/hr.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
April 3, 2012
Assignee:
The UAB Research Foundation
Inventors:
Ashita Tolwani, Rajesh Speer, Brenda Stofan
Abstract: The invention relates to process for making highly concentrated, spherical biopolymer gel particle suspensions comprising particles of defined particle diameter (e.g., range of 1 to 50?) utilizing high internal phase emulsion as an intermediate.
Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
Abstract: The invention relates to highly concentrated, spherical, biopolymer gel particle suspensions comprising particle of defined particle diameter range (e.g., 1 to 50?) and process for preparing the suspensions utilizing high internal phase emulsion as intermediate.
Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use.
Abstract: Methods of inhibiting cancer cell growth using HDAC10 inhibitors are provided. Methods of treating cancer in a subject using HDAC10 inhibitors are also provided. In certain embodiments, at least one second inhibitor selected from an autophagy inhibitor, an AMPK inhibitor, and methyl pyruvate is also used in the methods. Dose packs comprising HDAC10 inhibitors and at least one second inhibitor are provided. Methods of identifying HDAC10 inhibitors are also provided.
Type:
Application
Filed:
November 10, 2009
Publication date:
March 22, 2012
Inventors:
Tso-pang Yao, Hitoshi Sasajima, Yoshiharu Kawaguchi, Kai Cui, Chun-Hsiang Lai
Abstract: The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.
Type:
Application
Filed:
March 26, 2010
Publication date:
March 22, 2012
Applicant:
PULMATRIX, INC.
Inventors:
Richard Batycky, David L. Hava, Robert W. Clarke, Michal M. Lipp
Abstract: Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-?-boswellic acid, 11-keto-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 9,11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, ?-boswellic acid, acetyl-?-boswellic acid, 11-dehydro-?-boswellic acid, acetyl-9,11-dehydro-?-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans.
Type:
Application
Filed:
September 22, 2011
Publication date:
March 22, 2012
Applicant:
Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.
Abstract: Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.
Abstract: Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions.
Abstract: A method for improving the mildness of a cleansing composition includes 0.1 to 15 wt. % of a combination of a lactate salt and a gluconate salt is provided in a cleansing composition comprising 4-55 wt. % of a surfactant and water, wherein the lactate salt makes up 10-90 wt. % of the total of the lactate salt and the gluconate salt, the lactate salt being selected from one or more of sodium lactate, potassium lactate, ammonium lactate, calcium lactate, and triethanolamine lactate and the gluconate salt being selected from one or more of sodium gluconate, potassium gluconate, ammonium gluconate, calcium gluconate, and triethanolamine gluconate. The A cleansing composition, a method for the manufacture thereof, and to the use of the stipulated salts to improve mildness is also described.
Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, and derivatives thereof, and methods of using the same for improving the health, growth, and feed efficiency of livestock and fish as well as the quantity of meat produced in livestock in particular.
Abstract: The present disclosure includes compositions and methods of inactivating pathogens of a genital tract of a female. The compositions include L-lactic acid substantially free of D-lactic acid. In particular, an intravaginal ring for sustained release of L-lactic acid out of a reservoir containing multi-gram quantities of L-lactic acid, with minimal osmotically induced swelling or pressurization of the reservoir during prolonged use is provided.
Type:
Application
Filed:
May 28, 2010
Publication date:
March 22, 2012
Inventors:
Thomas R. Moench, Deirdre E. O'Hanlon, Richard A. Cone
Abstract: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and offspring mortality of animals.
Abstract: Described herein are novel analogs of 2-propylpentanoic acid, pharmaceutical compositions comprising the same, and methods of using the same for the treatment of diseases or conditions that are beneficially treated by administering a GABAAergic transmission enhancer and/or a histone deacetylase (HDAC) inhibitor.
Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.
Type:
Application
Filed:
March 18, 2011
Publication date:
March 22, 2012
Applicant:
The Regents of the University of Colorado
Inventors:
Daniel J. Abrams, Raymond Bunch, Tom Anchordoquy, Karen Elizabeth Stevens
Abstract: The present invention relates to a new composition and methods for preventing the transmission of enterohemorrhagic E. coli and other foodborne pathogens to farm animals. In accordance with one embodiment, a composition comprising lactic acid and acidic calcium sulfate, and a compound selected from the group consisting of caprylic acid, sodium benzoate, butyric acid and chlorine dioxide is provided as an inhibitor of the growth of enterohemorrhagic E. coli and other foodborne pathogens.
Type:
Grant
Filed:
January 25, 2006
Date of Patent:
March 20, 2012
Assignee:
University of Georgia Research Foundation, Inc.
Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.
Abstract: The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols.
Type:
Application
Filed:
November 21, 2011
Publication date:
March 15, 2012
Applicant:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA TEC Edmonton
Abstract: Provided is a composition for preventing hair loss or promoting hair growth including valproic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition may be applied to various industrial fields, including pharmaceutical, cosmetic and beauty aid industries.
Type:
Application
Filed:
May 11, 2010
Publication date:
March 15, 2012
Inventors:
Hyoung-Jun Kim, Won Seok Park, Hyun Ju Koh, Pil Joon Park, Su Na Kim, Kang-Yell Choi, Ju-Yong Yoon, Soung-Hoon Lee
Abstract: A composition comprising an inorganic particulate material in an amount of about 20 wt % to about 70 wt %, a carrier for the particulate material comprising a compound of formula (I) in an amount of about 1 wt % to about 70 wt %, a particulate material coating material in an amount of about 0 wt % to about 5 wt %, and a dispersing agent for the particulate material in an amount of about 0 wt % to about 5 wt %, based on the total weight of the composition, wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, and the non-alkoxy R1 or R2 is hydrogen; and R3 is a straight or branched chain C1-C30 alkyl radical.
Type:
Grant
Filed:
September 4, 2009
Date of Patent:
March 13, 2012
Assignee:
Hallstar Innovations Corp.
Inventors:
Craig A. Bonda, Anna Pavlovic, Jean Zhang